Adenosine A1 receptors modulate the anxiolytic-like effect of ethanol in the elevated plus-maze in mice

European Journal of Pharmacology
Rui D S PredigerReinaldo N Takahashi

Abstract

The anxiolytic property of ethanol is generally accepted to be an important motivational factor for its consumption and the development of alcohol dependence. Recent studies suggest that adenosine receptors mediate important actions of ethanol, such as motor incoordination and hypnotic effects. In addition, several lines of evidence support the involvement of adenosine in anxiety. The aim of the present study was to evaluate the role of adenosine receptors in the anxiolytic-like effect of ethanol in mice. The effects of acute administration of the adenosine receptor antagonists caffeine (nonselective), 8-cyclopentyl-1,3-dipropylxanthine (DPCPX, adenosine A1 receptor antagonist) and 4-(2-[7-amino-2-[2-furyl][1,2,4]triazolo-[2,3-a][1,3,5]triazin-5-yl-amino]ethyl)phenol (ZM241385, adenosine A(2A) receptor antagonist), together with the adenosine A1 receptor agonist 2-chloro-N6-cyclopentyladenosine (CCPA), and their interaction with ethanol in the elevated plus-maze test in mice were studied. The highest doses of caffeine (30.0 mg/kg, i.p.) and DPCPX (6.0 mg/kg, i.p.) produced an anxiogenic-like effect, while CCPA administration (0.25 mg/kg, i.p.) showed an anxiolytic-like activity. The prior administration of "non-anxiogenic" dose...Continue Reading

References

Dec 31, 1975·Psychopharmacologia·H M FranksG A Starmer
Nov 1, 1990·Psychological Bulletin·D B Newlin, J B Thomson
Jan 10, 1989·European Journal of Pharmacology·H A BaldwinS E File
Jan 1, 1987·Psychopharmacology·R G Lister
May 1, 1988·Pharmacology, Biochemistry, and Behavior·M Clark, M S Dar
Aug 1, 1988·Pharmacology, Biochemistry, and Behavior·S E FileL J Wilks
Jan 1, 1981·Neuroscience and Biobehavioral Reviews·L A Pohorecky
May 1, 1981·Proceedings of the National Academy of Sciences of the United States of America·S H SnyderJ W Daly
Oct 3, 1983·Life Sciences·M S DarW R Wooles
Aug 1, 1995·Alcoholism, Clinical and Experimental Research·Z H Meng, M S Dar
Oct 1, 1995·British Journal of Pharmacology·N JainT W Stone
Jan 1, 1997·Journal of Psychopharmacology·S K BhattacharyaA Chakrabarti
May 26, 1998·Psychopharmacology·C FlorioR Vertua
Jul 31, 1998·Progress in Neuro-psychopharmacology & Biological Psychiatry·V S Barwick, M S Dar
May 29, 1999·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·S L Blatt, R N Takahashi
Jul 19, 2000·Pharmacology, Biochemistry, and Behavior·V M FerreiraG S Morato
Nov 25, 2000·Alcohol·C J LaBuda, P N Fuchs
May 30, 2001·Drug and Alcohol Dependence·A Liguori, J H Robinson
Jul 27, 2001·Proceedings of the National Academy of Sciences of the United States of America·B JohanssonB B Fredholm
Feb 18, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Christopher L DrakeThomas Roth
Aug 21, 2003·Progress in Neurobiology·Mark J Millan
Oct 8, 2003·Behavioural Brain Research·Undine E LangDavid P Wolfer
Oct 24, 2003·Neuropharmacology·M El YacoubiJ-M Vaugeois

❮ Previous
Next ❯

Citations

Jan 13, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Rui D S PredigerReinaldo N Takahashi
Sep 1, 2011·Journal of Caffeine Research·Sergi Ferré, Mary Claire O'Brien
Sep 18, 2009·Alcohol and Alcoholism : International Journal of the Medical Council on Alcoholism·Tracy R ButlerMark A Prendergast
Jul 21, 2009·Behavioural Pharmacology·Paula Matias SoaresSilvânia Maria Mendes Vasconcelos
Dec 3, 2014·Progress in Neuro-psychopharmacology & Biological Psychiatry·Robin OrtizRodrigo Machado-Vieira
Jun 7, 2005·Expert Opinion on Emerging Drugs·Raye Z LittenMark Egli
Apr 15, 2014·Neuroscience·A P ArdaisL O Porciúncula
Sep 13, 2011·Progress in Neurobiology·Geoffrey BurnstockPeter Illes
Jul 29, 2009·Pharmacology, Biochemistry, and Behavior·Cristie Grazziotin NoschangCarla Dalmaz
Sep 11, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Tayfun I Uzbay
Dec 10, 2015·Journal of Caffeine Research·Abigail E KennedyWilliam J Warzak
Jul 19, 2011·Alcoholism, Clinical and Experimental Research·Tracy R Butler, Mark A Prendergast
Apr 19, 2011·Basic & Clinical Pharmacology & Toxicology·Caio MaximinoAnderson M Herculano
Apr 21, 2011·Pharmacology, Biochemistry, and Behavior·Dennis E RhoadsLucas J Rhoads
Aug 23, 2011·The International Journal of Neuropsychopharmacology·Daniela F FukushiroRoberto Frussa-Filho
Mar 7, 2017·The European Journal of Neuroscience·Lucas LuongMaxim Volgushev
Apr 7, 2017·Neuron·Bryce A ManderMatthew P Walker
Jan 9, 2016·Molecular Neurobiology·Roberto Farina AlmeidaDiogo Onofre Souza
Jul 11, 2008·Critical Reviews in Toxicology·Edward J Calabrese
May 29, 2020·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·E K EricksonR A Harris
Nov 18, 2016·Frontiers in Behavioral Neuroscience·Laura López-CruzMercé Correa
Dec 10, 2020·International Journal of Molecular Sciences·Monica FrinchiGiuseppa Mudò

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.